(function(){var e={2621:function(e,t,n){var i={"./Shared.css":33985,"./apple-touch-icon.png":70209,"./favicon-32x32.png":12668,"./logo.svg":68112,"./preview.jpg":72773};function a(e){var t=o(e);return n(t)}function o(e){if(!n.o(i,e)){var t=new Error("Cannot find module '"+e+"'");throw t.code="MODULE_NOT_FOUND",t}return i[e]}a.keys=function(){return Object.keys(i)},a.resolve=o,e.exports=a,a.id=2621},82275:function(e,t,n){"use strict";var i=n(45130),a=n(56768),o=n(96450),s=n(98477);const l={id:"app",class:"wrapper-for-outer-flexbox"},r={class:"app-container"},c=(0,a.Lk)("div",{class:"footnote-container"},[(0,a.Lk)("span",{class:"footnote text-grey-lighten-1"},"Modified from Grimes and Shulz, Lancet 2002; 359: 57–61 ")],-1);function u(e,t,n,i,u,d){const p=(0,a.g2)("outcomes-navbar"),h=(0,a.g2)("router-view"),f=(0,a.g2)("outcomes-footer"),m=(0,a.g2)("outcomes-research-wrapper");return(0,a.uX)(),(0,a.Wv)(o.E,null,{default:(0,a.k6)((()=>[(0,a.bF)(s.Y,null,{default:(0,a.k6)((()=>[(0,a.bF)(m,{_title:"Statistical Power Applet"},{default:(0,a.k6)((()=>[(0,a.bF)(p),(0,a.Lk)("div",l,[(0,a.Lk)("div",r,[(0,a.bF)(h)]),c]),(0,a.bF)(f,{copyright:u.copyright},null,8,["copyright"])])),_:1})])),_:1})])),_:1})}var d={name:"App",data(){return{copyright:"© 2024 Washington University School of Medicine, St. Louis, Missouri"}}},p=n(71241);const h=(0,p.A)(d,[["render",u]]);var f=h,m=(n(35524),n(35790)),g=(0,m.$N)();async function v(){const e=await n.e(53).then(n.t.bind(n,48874,23));e.load({google:{families:["Roboto:100,300,400,500,700,900&display=swap"]}})}var b=n(50973),k=(n(44114),n(70554)),y=n(4189),L=n(39180),w=n(91606),W=n(30697),x=n(93745);function C(e,t,n,i,o,s){return(0,a.uX)(),(0,a.Wv)(y.J,{class:"mx-auto my-12 container"},{default:(0,a.k6)((()=>[(0,a.bF)(L.m,null,{default:(0,a.k6)((()=>[(0,a.bF)(w.r,null,{default:(0,a.k6)((()=>[(0,a.eW)("Clinical Research Study Design")])),_:1})])),_:1}),(0,a.bF)(W.O,null,{default:(0,a.k6)((()=>[(0,a.eW)("Choosing the right study design is crucial for clinicians and researchers to critically evaluate medical literature and design their own studies. This step by step tool asks a series of questions to determine the most appropriate study design for your context. At any stage, you can jump to a visual representation of the decision tree and see the choices you've made and what comes next. ")])),_:1}),(0,a.bF)(W.O,null,{default:(0,a.k6)((()=>[(0,a.eW)(" We'll first distinguish between experimental and observational studies, then narrow down to subtypes such as randomised trials, cohort studies, or case-control studies. This structured path ensures that researchers select the most appropriate design for each situation, improving the quality and ability to communicate the results of clinical research. ")])),_:1}),(0,a.bF)(x.S,null,{default:(0,a.k6)((()=>[(0,a.bF)(k.D,{text:"Begin",variant:"text",style:{marginLeft:"auto"},onClick:t[0]||(t[0]=t=>e.$router.push({name:"DecisionTree"}))})])),_:1})])),_:1})}var _={name:"IntroCard"};const S=(0,p.A)(_,[["render",C],["__scopeId","data-v-3a2c8d2a"]]);var F=S,T=n(24232),z=n(95523),E=n(19336);const A={style:{display:"flex",flexGrow:1}},M={className:"mr-5",style:{wordWrap:"break-spaces",flexGrow:1,marginRight:"auto"}},R={className:"hideOnDesktop",style:{maxWidth:"fit-content"}},I={key:0,className:"chips"},D={className:"showOnDesktop"},U={class:"choices-container"};function V(e,t,n,o,s,l){const r=(0,a.g2)("DropdownMenu"),c=(0,a.g2)("step-card");return(0,a.uX)(),(0,a.CE)("div",null,[(0,a.bF)(i.eB,{name:"fade",mode:"out-in"},{default:(0,a.k6)((()=>[(0,a.bF)(y.J,{class:"mx-auto my-12 container"},{default:(0,a.k6)((()=>[(0,a.bF)(E.Z,{color:"red-darken-4",height:"5","model-value":l.progress,class:"progressBarTag"},null,8,["model-value"]),(0,a.bF)(L.m,null,{default:(0,a.k6)((()=>[(0,a.bF)(w.r,{className:"v-card-title card-title-bar"},{default:(0,a.k6)((()=>[(0,a.Lk)("div",A,[(0,a.Lk)("span",M,(0,T.v_)(l.currentQuestion.title),1),(0,a.Lk)("span",R,[(0,a.bF)(r,{stepId:l.currentQuestion.id},null,8,["stepId"])])]),l.breadcrumbs.length?((0,a.uX)(),(0,a.CE)("span",I,[((0,a.uX)(!0),(0,a.CE)(a.FK,null,(0,a.pI)(l.breadcrumbs,(e=>((0,a.uX)(),(0,a.Wv)(z.x,{key:e.title,color:e.color,tonal:""},{default:(0,a.k6)((()=>[(0,a.eW)((0,T.v_)(e.title),1)])),_:2},1032,["color"])))),128))])):(0,a.Q3)("",!0),(0,a.Lk)("span",D,[(0,a.bF)(r,{stepId:l.currentQuestion.id},null,8,["stepId"])])])),_:1})])),_:1}),(0,a.bF)(L.m,null,{default:(0,a.k6)((()=>[((0,a.uX)(),(0,a.Wv)((0,a.$y)(l.currentQuestion.component)))])),_:1}),l.currentQuestion.choices&&l.currentQuestion.choices.length?((0,a.uX)(),(0,a.Wv)(L.m,{"selected-class":"bg-primary",key:l.currentQuestion.id,class:"flex flex-wrap"},{default:(0,a.k6)((()=>[(0,a.Lk)("div",U,[((0,a.uX)(!0),(0,a.CE)(a.FK,null,(0,a.pI)(l.currentQuestion.choices,(e=>((0,a.uX)(),(0,a.Wv)(c,{key:e.answer,title:e.answer,description:e.option_description,currentlySelected:this.nextStep===e.next,onClick:t=>l.setNextStep(e.next)},null,8,["title","description","currentlySelected","onClick"])))),128))])])),_:1})):(0,a.Q3)("",!0),(0,a.bF)(x.S,null,{default:(0,a.k6)((()=>[s.path.length>0?((0,a.uX)(),(0,a.Wv)(k.D,{key:0,text:"Back",variant:"text",onClick:l.goBack},null,8,["onClick"])):((0,a.uX)(),(0,a.Wv)(k.D,{key:1,text:"Back to Intro",variant:"text",onClick:t[0]||(t[0]=t=>e.$router.push({name:"IntroMessage"}))})),this.steps[this.currentStep].choices?((0,a.uX)(),(0,a.Wv)(k.D,{key:2,text:"Next",variant:"text",style:{marginLeft:"auto"},onClick:t[1]||(t[1]=e=>l.advanceTree()),disabled:!this.nextStep},null,8,["disabled"])):(0,a.Q3)("",!0),this.steps[this.currentStep].choices||this.steps[this.currentStep].next?(0,a.Q3)("",!0):((0,a.uX)(),(0,a.Wv)(k.D,{key:3,text:"Start over",variant:"text",style:{marginLeft:"auto"},onClick:t[2]||(t[2]=e=>l.startOver())})),"statement"===this.steps[this.currentStep].type&&this.steps[this.currentStep].next?((0,a.uX)(),(0,a.Wv)(k.D,{key:4,text:"Continue",variant:"text",style:{marginLeft:"auto"},onClick:t[3]||(t[3]=()=>{l.setNextStep(l.currentQuestion.next),l.advanceTree()})})):(0,a.Q3)("",!0)])),_:1})])),_:1})])),_:1})])}function q(e,t,n,i,o,s){return(0,a.uX)(),(0,a.Wv)(y.J,{class:"mx-auto my-12","max-width":"374",color:s.getBackgroundColor},{default:(0,a.k6)((()=>[(0,a.bF)(L.m,null,{default:(0,a.k6)((()=>[(0,a.bF)(w.r,{class:"card-title"},{default:(0,a.k6)((()=>[(0,a.eW)((0,T.v_)(n.title),1)])),_:1})])),_:1}),n.description?((0,a.uX)(),(0,a.Wv)(W.O,{key:0},{default:(0,a.k6)((()=>[(0,a.eW)((0,T.v_)(n.description),1)])),_:1})):(0,a.Q3)("",!0)])),_:1},8,["color"])}var O={props:{supportCopyText:{default:!1},supportSeeExample:{default:!1},disabled:{default:!1},identifier:{default:""},currentlySelected:{default:!1},title:{default:void 0},description:{default:""},unselectable:{default:!1},width:{default:"calc(50% - 30px)"},subtitle:{default:void 0}},data(){return{selection:1}},components:{},computed:{getBackgroundColor(){return this.currentlySelected?"success":""}}};const P=(0,p.A)(O,[["render",q],["__scopeId","data-v-62ea7444"]]);var Y=P;const N="assignExposures",X="experimentalStudy",G="randomizedControlledTrial",j="nonRandomizedControlledTrial",B="randomAssignment",H="newTreatmentBetter",Q="superiorityTrial",K="equivalenceTrial",J="observationalStudy",$="analyticalStudy",Z="caseControlStudy",ee="crossSectionalStudy",te="comparisonGroup",ne="researchDirection",ie="subjectCount",ae="descriptiveStudy",oe="caseReport",se="caseSeries",le="cohortPerspective",re="prospectiveCohort",ce="retrospectiveCohort";var ue={[X]:{type:"statement",title:"Experimental Study",id:X,component:"ExperimentalStudyDescription",next:B,color:"blue-lighten-2",inputs:[N]},[B]:{type:"question",id:B,title:"Were participants randomly assigned?",component:"RandomAllocationDescription",choices:[{answer:"Yes",next:G,option_description:"Participants were randomly assigned"},{answer:"No",next:j,option_description:"Participants were not randomly assigned"}],inputs:[X]},[G]:{type:"statement",id:G,title:"Randomized Clinical Trial",flowChartTitle:"Randomized\nClinical Trial",component:"RandomizedControlledTrialDescription",next:H,color:"blue-darken-2",inputs:[B]},[H]:{type:"question",id:H,title:"Is the aim of the study to demonstrate a new treatment is significantly better than existing treatment or placebo?",flowChartTitle:"Is the aim of the study to demonstrate\na new treatment is significantly better than\nexisting treatment or placebo?",component:"NewTreatmentBetter",choices:[{answer:"Yes",next:Q},{answer:"No",next:K}],inputs:[G]},[Q]:{type:"statement",id:Q,title:"Superiority Trial",leaf:!0,component:"SuperiorityTrial",color:"indigo-darken-4",inputs:[H]},[K]:{type:"statement",id:K,title:"Equivalence or Non-Inferiority Trial",flowChartTitle:"Equivalence or\nNon-Inferiority Trial",leaf:!0,component:"EquivalenceTrial",color:"indigo-darken-4",inputs:[H]},[j]:{type:"statement",id:j,title:"Non-randomized Clinical Trial",flowChartTitle:"Non-randomized\nClinical Trial",leaf:!0,component:"NonRandomizedControlledTrialDescription",color:"indigo-darken-4",inputs:[B]}};const de={[$]:{type:"statement",title:"Analytical Study",id:$,component:"AnalyticalStudyDescription",next:ne,color:"green-darken-2",inputs:[te]},[ne]:{type:"question",title:"What is the direction of research?",flowChartTitle:"What is the direction\nof research?",id:ne,component:"DirectionDescription",inputs:[$],choices:[{answer:"Exposure\n→\nOutcome",next:le,option_description:"Exposure leads to outcome"},{answer:"Outcome\n→\nExposure",next:Z,option_description:"Outcome leads to exposure"},{answer:"Exposure\n<?>\nOutcome",next:ee,option_description:"Relationship between exposure and outcome is indeterminate"}]},[le]:{type:"question",title:"What is the perspective of the researcher relative to the data under study?",flowChartTitle:"What is the perspective of the\nresearcher relative to\nthe data under study?",id:le,component:"PerspectiveQuestion",inputs:[ne],choices:[{answer:"Prospective",next:re,option_description:"Outcomes tracked moving forward in time"},{answer:"Retrospective",next:ce,option_description:"Outcomes tracked by examining past records"}]},[re]:{type:"statement",title:"Prospective Cohort Study",id:re,leaf:!0,inputs:[le],component:"ProspectiveCohortStudyDescription",color:"teal-darken-4",choices:[]},[ce]:{type:"statement",title:"Retrospective Cohort Study",id:ce,leaf:!0,inputs:[le],component:"RetrospectiveCohortStudyDescription",color:"teal-darken-4",choices:[]},[Z]:{type:"statement",title:"Case Control Study",id:Z,leaf:!0,inputs:[ne],component:"CaseControlStudyDescription",color:"teal-darken-4",choices:[]},[ee]:{type:"statement",title:"Cross Sectional Study",flowChartTitle:"Cross Sectional\nStudy",id:ee,leaf:!0,inputs:[ne],component:"CrossSectionalStudyDescription",color:"teal-darken-4",choices:[]}},pe={[ae]:{type:"statement",title:"Descriptive Study",id:ae,component:"DescriptiveStudyDescription",next:ie,inputs:[te],color:"green-darken-2"},[ie]:{type:"question",title:"How many subjects were there?",flowChartTitle:"How many subjects\nwere there?",id:ie,component:"HowManySubjctsDescription",inputs:[ae],choices:[{answer:"One subject",next:oe},{answer:"More than\none",next:se}]},[oe]:{type:"statement",title:"Case Report",id:oe,leaf:!0,inputs:[ie],component:"CaseReportDescription",color:"teal-darken-4"},[se]:{type:"statement",title:"Case Series",id:se,leaf:!0,inputs:[ie],component:"CaseSeriesDescription",color:"teal-darken-4"}};var he={[J]:{type:"statement",title:"Observational Study",id:J,component:"ObservationalStudyDescription",next:te,color:"green-lighten-2",inputs:[N]},[te]:{type:"question",id:te,title:"Was there a comparison group?",component:"ComparisonGroupDescription",inputs:[J],choices:[{answer:"Yes",next:$,option_description:"A comparison group was used"},{answer:"No",next:ae,option_description:"No comparison group was used"}]},...de,...pe},fe={[N]:{id:N,title:"Did the investigator assign exposures?",flowChartTitle:"Did the investigator\nassign exposures?",component:"AssignExposures",inputs:[],choices:[{answer:"Yes",next:X,option_description:"Investigator did assign exposures"},{answer:"No",next:J,option_description:"Investigator did not assign exposures"}]},...ue,...he};function me(e,t){const n={...t[e]};if(!e||!n||n.leaf)return 0;let i=0;n.choices||"statement"!==n.type||(n.choices=[{next:n.next}]);for(const a of n.choices)if(a.next){const e=1+me(a.next,t);i=Math.max(i,e)}else i=Math.max(i,1);return i}function ge(e){const t=fe[e];if(!t)return console.error("Invalid step name:",e),[];if(!t.inputs||0===t.inputs.length)return[t.id];const n=t.inputs.flatMap((e=>ge(e)));return[...n,e]}function ve(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("p",null," The key distinction between experimental studies and observational studies lies in the level of control the investigator has over exposure or intervention. ")}var be={name:"AssignExposures"};const ke=(0,p.A)(be,[["render",ve],["__scopeId","data-v-3bcae525"]]);var ye=ke,Le=n(10381),we=n(76686),We=n(37604),xe=n(29880);const Ce=(0,a.Lk)("p",null," Randomization is a crucial aspect of randomized clinical trials (RCTs). It involves the random assignment of participants to different intervention groups. This is done to ensure that, on average, known and unknown factors that could influence treatment response are evenly distributed across groups, allowing for a fair comparison. ",-1),_e=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Simple Randomization"),(0,a.eW)(": Participants are randomly assigned to different treatment groups without any specific stratification or blocking. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Stratified Randomization"),(0,a.eW)(": Ensures balance in important baseline characteristics by dividing participants into strata based on certain factors (e.g., age, gender) and then randomizing within each stratum. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Blocked Randomization"),(0,a.eW)(": Participants are randomized in blocks, and each block contains an equal number of participants from each treatment group. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Minimization"),(0,a.eW)(": A dynamic randomization method that minimizes differences between groups by adjusting for specific baseline characteristics. ")])],-1),Se=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null," Achieves balance in known and unknown factors between intervention groups. "),(0,a.Lk)("li",null," Enhances the internal validity of the study by reducing the risk of confounding. ")],-1),Fe=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,"Impractical or unethical in certain situations."),(0,a.Lk)("li",null," Blinding may not always be feasible, leading to potential bias. ")],-1);function Te(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[Ce,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",direction:i.isMobile?"vertical":"horizontal",class:"mb-3"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"commonMethods"},{default:(0,a.k6)((()=>[(0,a.eW)("Common Randomization Methods")])),_:1}),(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"commonMethods"},{default:(0,a.k6)((()=>[_e])),_:1}),(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[Se])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[Fe])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var ze=n(90144);function Ee(){const e=(0,ze.KR)(window.innerWidth),t=()=>{e.value=window.innerWidth};(0,a.sV)((()=>{window.addEventListener("resize",t)})),(0,a.xo)((()=>{window.removeEventListener("resize",t)}));const n=(0,a.EW)((()=>e.value<=600));return{windowWidth:e,isMobile:n}}var Ae={name:"RandomizationInfo",setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const Me=(0,p.A)(Ae,[["render",Te]]);var Re=Me;function Ie(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("p",null," In an experimental study, the researcher actively intervenes by assigning subjects to different exposures or interventions. The investigator controls who receives the experimental treatment and who serves as a control group. ")}var De={name:"ExperimentalStudyDescription"};const Ue=(0,p.A)(De,[["render",Ie]]);var Ve=Ue;const qe=(0,a.Lk)("p",null," Participants are randomly assigned to different interventions and baseline characteristics should be comparable between groups. Control and experimental interventions are administered based on random assignment. Outcomes are assessed and compared between the control and experimental intervention to evaluate the impact of the intervention. Randomized clinical trials are a powerful and widely accepted method for evaluating the causal relationship between an intervention and an outcome. ",-1),Oe=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Causality inference"),(0,a.eW)(": RCTs provide a strong basis for inferring causality due to the random assignment of participants. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Minimization of confounding"),(0,a.eW)(": Randomization minimizes the impact of known and unknown confounding variables, allowing for a more accurate assessment of treatment effects. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Comparability of groups"),(0,a.eW)(": Achieves baseline comparability, ensuring that differences in outcomes can be attributed to the intervention. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Minimization"),(0,a.eW)(": A dynamic randomization method that minimizes differences between groups by adjusting for specific baseline characteristics. ")])],-1),Pe=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"External validity concerns"),(0,a.eW)(": Strict inclusion/exclusion criteria and controlled settings may limit the generalizability of findings to real-world populations. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Ethical limitations"),(0,a.eW)(": Randomization may not be ethical or practical in certain situations. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Practical challenges"),(0,a.eW)(": Recruitment, retention, and adherence issues may affect the feasibility and reliability of RCTs. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Resource intensive"),(0,a.eW)(": Conducting RCTs can be time-consuming and expensive. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Potential for bias"),(0,a.eW)(": Despite randomization, bias can still occur if there are issues with blinding, adherence, or other study procedures. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Analytical challenges"),(0,a.eW)(": Subjects can drop out or switch between treatments, which makes analysis and interpretation very challenging. ")])],-1),Ye=(0,a.Lk)("p",null," To critically appraise RCTs, consider factors such as randomization, use of blinding, adequate sample size to provide precise estimates, and outcome measurement. There are several types of bias that can potentially impact RCTs. Here are the main types to consider. ",-1),Ne=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection bias"),(0,a.eW)(": This bias can occur if there is a systematic difference in the characteristics of participants assigned to different treatment groups. For example, if the randomization process fails to properly balance important factors between the groups, it can introduce bias and affect the validity of the trial results. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Performance bias"),(0,a.eW)(": This bias can arise when participants or care providers are aware of the assigned treatments, which may influence their behavior or decision-making during the trial. To mitigate this bias, blinding or masking techniques are often employed to maintain participant and/or provider unawareness of the assigned treatments. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Detection bias"),(0,a.eW)(": Also known as ascertainment bias or observer bias, this occurs when outcome assessors are influenced by their knowledge of the treatment group assignments, leading to biased assessment or interpretation of outcomes. Blinding assessors to treatment allocation can help minimize this bias. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Attrition bias"),(0,a.eW)(": This bias occurs when participants drop out from the study, and their reasons for dropping out may be related to their treatment or outcome status, resulting in incomplete or biased data. High attrition rates can impact the generalizability of the findings and introduce bias if not appropriately addressed. ")])],-1),Xe=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"1b"),(0,a.eW)(".")],-1),Ge=(0,a.Lk)("p",null," This refers to evidence derived from well-conducted randomized clinical trials (RCTs) with a narrow confidence interval. In Level 1b evidence, the research is based on high-quality RCTs that include appropriate randomization methods and have effectively controlled for biases. These trials often involve enough participants to provide statistical power for drawing reliable conclusions. The narrow confidence interval indicates a precise estimation of the treatment effect, reducing uncertainty. ",-1),je=(0,a.Lk)("p",null," Level 1b evidence is among the highest levels of evidence available. It provides valuable information on the effectiveness of interventions, treatments, or therapies, offering robust evidence for clinical decision-making. ",-1),Be=(0,a.Lk)("h4",{class:"my-4"}," Does the new drug X effectively lower blood pressure in individuals with hypertension compared to a placebo? ",-1),He=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study design"),(0,a.eW)(": Randomized controlled trial (RCT) ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study population"),(0,a.eW)(": Adults (age 35-70) diagnosed with hypertension, without any contraindications for the study drug X, and not currently on any other antihypertensive medications. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Dependent variables"),(0,a.eW)(": Blood pressure measurements (systolic and diastolic). ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Duration of follow-up"),(0,a.eW)(": 12 weeks.")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Primary outcome measure"),(0,a.eW)(": Change in systolic blood pressure from baseline to week 12. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Clinically meaningful difference"),(0,a.eW)(": A reduction in systolic blood pressure of 10 mmHg or more is considered clinically meaningful in managing hypertension. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample size calculation and power"),(0,a.eW)(": Assuming a two-sided significance level of 0.05 and statistical power of 80%, a prior study found that a mean reduction of 10 mmHg in systolic blood pressure with a standard deviation of 12 mmHg is clinically meaningful. Considering this information, an estimated total sample size of 200 participants would be needed. This calculation would provide enough statistical power to detect a clinically meaningful difference. ")])],-1);function Qe(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[qe,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-3",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[(0,a.eW)("Cricial Appraisal")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[Oe])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[Pe])),_:1}),(0,a.bF)(xe.Y,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[Ye,Ne])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[Xe,Ge,je])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[Be,He])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var Ke={name:"RandomizedControlledTrialDescription",setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const Je=(0,p.A)(Ke,[["render",Qe]]);var $e=Je;const Ze=(0,a.Lk)("p",null," Investigator does assign interventions, but those interventions are not randomly assigned. Examples include before-and-after studies, time series studies, and non-equivalent control group designs. Investigators may choose to use a non-randomized clinical trial design instead of a randomized clinical trial (RCT) design in various situations. Here are a few scenarios. ",-1),et=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Real-World context"),(0,a.eW)(": Non-randomized trials often reflect real-world clinical practice and provide insights into the effectiveness and safety of interventions in routine settings. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Ethical considerations"),(0,a.eW)(": In some cases, it may be ethically challenging or deemed inappropriate to randomize participants to different treatment groups. For example, if a treatment is believed to be highly effective and withholding it from a control group would be unethical, a non-randomized design may be used. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Cost and feasibility"),(0,a.eW)(": Conducting RCTs can be resource-intensive and may require significant time, funding, and logistical support. In situations where these resources are limited, a non-randomized design can be a more feasible option. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Exploratory or Hypothesis-Generating Studies"),(0,a.eW)(": Non-randomized designs can be useful when researchers aim to explore new treatments or interventions and generate hypotheses for further investigation. These designs allow for initial exploration of potential benefits or risks. ")])],-1),tt=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Potential bias"),(0,a.eW)(": Non-randomized trials are prone to various types of bias, which can distort the results and affect the validity of the conclusions. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Confounding factors"),(0,a.eW)(": Differences in baseline characteristics between treatment groups can confound the results and make it challenging to attribute observed effects solely to the interventions. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Limited internal validity"),(0,a.eW)(": Non-randomized designs may have limited internal validity due to the lack of random allocation, resulting in potential alternative explanations for observed outcomes. ")])],-1),nt=(0,a.Lk)("p",{class:"mb-5"}," To critically appraise non-randomized controlled trials, consider factors such as lack of randomization, use of blinding, was there adequate sample size to provide precise estimates, and use of validated and clinically relevant outcome measurements. ",-1),it=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection bias"),(0,a.eW)(": Selection bias can occur when the non-random allocation of participants to treatment groups can lead to systematic differences in patients that impacts the interpretation of results. ")])],-1),at=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"3"),(0,a.eW)(".")],-1),ot=(0,a.Lk)("p",{class:"mb-5"},' Level 3 evidence is categorized as "Non-randomized controlled cohort/follow-up study" within the CEBM levels of evidence framework. Non-randomized trials can contribute important information, especially in cases where conducting randomized controlled trials is challenging or not possible. ',-1),st=(0,a.Lk)("p",null," However, non-randomized trials should be interpreted with caution due to the potential for confounding factors and other biases that may influence the results. It is important to consider the limitations of non-randomized trials when assessing the strength of evidence. ",-1),lt=(0,a.Lk)("h4",{class:"my-4"}," Is treatment X (e.g., a targeted therapy blocking a specific pathway) superior to the standard treatment (e.g., chemotherapy) in slowing disease progression and reducing disability in patients with advanced non-small cell lung cancer? ",-1),rt=(0,a.Lk)("p",null," A non-randomized trial design was selected for pragmatic reasons. The non-randomized trial design allows researchers to evaluate the two interventions under conditions closer to routine clinical practice. This pragmatic approach offers additional information on treatment outcomes and experiences in a broader patient population. ",-1),ct=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study design"),(0,a.eW)(": Non-randomized superiority clinical trial ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study population"),(0,a.eW)(": Adults (age 18-75) diagnosed with advanced non-small cell lung cancer who meet the inclusion and exclusion criteria and are willing to participate. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Dependent variables"),(0,a.eW)(": Disease progression (e.g., tumor size, metastasis), disability (e.g., ability to perform daily activities), and safety profiles. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Duration of follow-up"),(0,a.eW)(": 1 year")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Primary outcome measure"),(0,a.eW)(": Disease progression-free survival (time to disease progression or death) ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Clinically meaningful difference"),(0,a.eW)(": In this non-randomized trial, a 20% improvement in disease progression-free survival is determined to be clinically meaningful, indicating that treatment X would need to demonstrate a 20% increase or reduction in the risk of disease progression or death compared to the standard treatment to be considered clinically superior. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample size calculation"),(0,a.eW)(": Assuming a significant difference in disease progression-free survival of 20% between treatment X and the standard treatment, with a two-sided significance level of 0.05 and a statistical power of 80%, a sample size calculation estimates a minimum of 200 participants (100 per group). ")])],-1);function ut(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[Ze,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-3",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[(0,a.eW)("Cricial Appraisal")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[et])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[tt])),_:1}),(0,a.bF)(xe.Y,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[nt,it])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[at,ot,st])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[lt,rt,ct])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var dt={setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const pt=(0,p.A)(dt,[["render",ut]]);var ht=pt;function ft(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("p",null," Analytical studies are hypothesis-driven investigations which test associations or causal relationships. ")}var mt={name:"AnalyticalStudyDescription"};const gt=(0,p.A)(mt,[["render",ft],["__scopeId","data-v-67441a6a"]]);var vt=gt;const bt=e=>((0,a.Qi)("data-v-7f63a2b9"),e=e(),(0,a.jt)(),e),kt=bt((()=>(0,a.Lk)("p",null," The direction of research refers to the temporal relationship between exposure and outcome. ",-1))),yt=bt((()=>(0,a.Lk)("p",null," Cohort studies examine the exposure first and then observe the occurrence of the outcome over time, aligning with the clinical pathway for inferring causality. ",-1))),Lt=bt((()=>(0,a.Lk)("p",null," Cohort studies provide more robust evidence of causality compared to case-control studies. ",-1))),wt=bt((()=>(0,a.Lk)("p",null," Understanding the direction of events helps avoid reverse causation, where the outcome influences the exposure. For instance, in a study linking high coffee consumption and sleep problems, reverse causation could occur if individuals consume more coffee to counteract existing sleep problems. To establish causality, the exposure should precede the outcome in time. ",-1)));function Wt(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)(a.FK,null,[kt,yt,Lt,wt],64)}var xt={name:"DirectionDescription"};const Ct=(0,p.A)(xt,[["render",Wt],["__scopeId","data-v-7f63a2b9"]]);var _t=Ct;const St=(0,a.Lk)("p",null," This type of cohort study follows a group of individuals over time, assessing their health outcomes based on certain exposures. Participants are enrolled based on their exposure status, and then followed over time to observe the occurrence of outcomes. Information on exposure and outcomes is collected at regular intervals throughout the study duration. Exposures and outcomes can be measured using various methods, including self-reporting, medical records, or laboratory tests. ",-1),Ft=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Temporality"),(0,a.eW)(": Establishes a clear temporal sequence between exposure and outcome, making it valuable for assessing causation. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Measure of incidence"),(0,a.eW)(": Can assess the incidence and cumulative risk of outcomes over time. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Controlled data collection"),(0,a.eW)(": Researchers can collect detailed and standardized information on exposures, reducing the risk of recall bias. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Outcome ascertainment"),(0,a.eW)(": Allows for real-time and standardized measurement of outcomes, enhancing accuracy. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Measurement of multiple exposures and outcomes"),(0,a.eW)(": Enables the study of multiple exposures and their combined effects on outcomes. Also allows for the study of multiple outcomes associated with a single exposure. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Minimizes recall bias"),(0,a.eW)(": Since data on exposures are collected before the outcome occurs, participants are less likely to be influenced by knowledge of the outcome. ")])],-1),Tt=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Time-Consuming and costly"),(0,a.eW)(": Prospective cohort studies are resource-intensive, requiring long-term follow-up and significant financial investment. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Loss to follow-up"),(0,a.eW)(": Participants may drop out or be lost to follow-up over the study duration, potentially introducing bias. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Not suitable for rare outcomes"),(0,a.eW)(": If the outcome of interest is rare, a large sample size and extended follow-up may be needed to observe enough events. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection bias"),(0,a.eW)(": Participants who stay in the study may differ systematically from those who drop out, leading to bias. ")])],-1),zt=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"2b"),(0,a.eW)(".")],-1),Et=(0,a.Lk)("p",null," Level 2b evidence refers to individual cohort studies with a low risk of bias or confounding. Level 2b evidence provides moderately strong evidence for evaluating the associations between exposures and outcomes. These studies offer valuable insights but must be interpreted with an understanding of their inherent limitations and potential biases. ",-1),At=(0,a.Lk)("p",null," In the hierarchy of evidence, Level 2b is more reliable than expert opinion or case series, but not as strong as randomized controlled trials or systematic reviews. This level of evidence can support clinical decision-making, especially when higher-quality evidence is lacking. ",-1),Mt=(0,a.Lk)("h4",{class:"my-4"}," Does adherence to a Mediterranean diet slow the progression of Type 2 Diabetes (T2D) compared to a standard Western diet? ",-1),Rt=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study population"),(0,a.eW)(": Adults (40-65 years), diagnosed with Type 2 Diabetes within the past 2 years, HbA1c levels between 6.5% and 9%, and BMI between 25 and 35 kg/m². Exclude pregnant or breastfeeding women, individuals with severe comorbid conditions (e.g., cancer, advanced cardiovascular disease), and those on medications known to significantly affect glucose metabolism (other than standard T2D medications). ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Intervention Group"),(0,a.eW)(": Participants following a Mediterranean diet, characterized by high consumption of fruits, vegetables, whole grains, legumes, and olive oil, moderate consumption of fish and poultry, and low consumption of red meat and sweets. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Control group"),(0,a.eW)(": Participants following a standard Western diet, characterized by higher intake of red meats, processed foods, and sweets, and lower intake of fruits and vegetables. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Outcome Measure"),(0,a.eW)(": Change in HbA1c levels over 12 months. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Clinically important change"),(0,a.eW)(": A reduction of 0.5% in HbA1c is considered clinically significant, as it is associated with a meaningful reduction in the risk of diabetes complications. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample size calculation and power"),(0,a.eW)(": Assuming a two-sided significance level of 0.05, statistical power of 80%, and a difference of 0.5% or greater as a clinically meaningful difference, an estimated total sample size of 152 (76 per group) would be needed. This calculation would provide enough statistical power to detect a clinically meaningful difference. ")])],-1);function It(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[St,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-3",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[Ft])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[Tt])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[zt,Et,At])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[Mt,Rt])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var Dt={setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const Ut=(0,p.A)(Dt,[["render",It]]);var Vt=Ut;const qt=(0,a.Lk)("p",null," This type of study is a type of observational study where researchers look back at historical data to investigate relationships between exposures and outcomes. In this design, two groups (cohorts) are identified based on their exposure status to a certain factor or intervention. Researchers then track these groups forward in time using existing records to see if there are differences in outcomes between the exposed and non-exposed cohorts. ",-1),Ot=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Cost and time efficiency"),(0,a.eW)(": Retrospective studies are generally quicker and more cost-effective than prospective studies. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Availability of historical data"),(0,a.eW)(": Useful for studying outcomes that have occurred in the past. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Multiple outcomes"),(0,a.eW)(": Allows the investigation of multiple outcomes related to the same exposure. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Suitable for rare outcomes"),(0,a.eW)(": If the outcome is rare, a retrospective design can efficiently capture events over a shorter time. ")])],-1),Pt=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Recall bias"),(0,a.eW)(": Participants may have difficulty accurately recalling past exposures, leading to bias. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Limited control over data quality"),(0,a.eW)(": The quality of historical data may vary, impacting the accuracy of exposure and outcome ascertainment. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Temporality challenges"),(0,a.eW)(": Establishing a clear temporal sequence between exposure and outcome can be challenging. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Confounding"),(0,a.eW)(": Since data are collected after the outcome has occurred, confounding variables may be more challenging to control. ")])],-1),Yt=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"2b"),(0,a.eW)(".")],-1),Nt=(0,a.Lk)("p",null," Level 2b evidence refers to individual cohort studies, including retrospective cohort studies, which provide moderate-quality evidence. These studies offer valuable insights but must be interpreted with an understanding of their inherent limitations and potential biases. ",-1),Xt=(0,a.Lk)("p",null," In the hierarchy of evidence, Level 2b is more reliable than expert opinion or case series, but not as strong as randomized controlled trials or systematic reviews. This level of evidence can support clinical decision-making, especially when higher-quality evidence is lacking. ",-1),Gt=(0,a.Lk)("h4",{class:"my-4"}," Does the new rehabilitation program improve functional outcomes in stroke patients more effectively than the standard rehabilitation program? ",-1),jt=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study Design"),(0,a.eW)(": Retrospective Cohort Study. The investigator will extract data from hospital records for all stroke patients who received either the new or standard rehabilitation program. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study Population"),(0,a.eW)(": Stroke patients who received rehabilitation at the hospital between 2010 and 2020. At this hospital, there were a total of 102 patients who received rehabilitation (53 standard therapy, 49 new rehabilitation) during this time. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Independent Variables"),(0,a.eW)(": "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("span",{className:"italic"},"Intervention Group"),(0,a.eW)(": Patients who underwent the new rehabilitation program. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{className:"italic"},"Control Group"),(0,a.eW)(": Patients who underwent the standard rehabilitation program. ")])])]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Outcome Measure"),(0,a.eW)(": Functional Independence Measure (FIM) scores, which assess the level of a patient's functional independence in various activities of daily living. "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("span",{className:"italic"},"Pre-Rehabilitation FIM Score"),(0,a.eW)(": FIM score before starting rehabilitation. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{className:"italic"},"Post-Rehabilitation FIM Score"),(0,a.eW)(": FIM score six months after completing rehabilitation. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{className:"italic"},"Within-Subject Difference"),(0,a.eW)(": The change in FIM score for each patient from pre- to post-rehabilitation. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{className:"italic"},"Between-Group Difference"),(0,a.eW)(": The difference in the average within-subject differences between the two groups. ")])])]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Minimal Clinically Important Difference"),(0,a.eW)(": A clinically meaningful change in FIM score is an improvement of 10 points. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample Size Calculation and Precision of the Effect Size Estimate"),(0,a.eW)(": "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null," In this scenario, the sample size is fixed at 102 patients who received rehabilitation (53 standard therapy, 49 new rehabilitation) during this time. "),(0,a.Lk)("li",null," The investigator estimates that the average within-subject difference in FIM for the patients who received the new rehabilitation program is 15 points (with a standard deviation of 5 points). "),(0,a.Lk)("li",null," The investigator estimates that the average within-subject difference in FIM for the patients who received the standard program is 10 points (with a standard deviation of 5 points). "),(0,a.Lk)("li",null," The between-group difference is estimated to be 5 points (15 points - 10 points). "),(0,a.Lk)("li",null," Given the fixed sample size of 102 and the expected results, the precision of the effect size estimate (between-group difference of 5 points) is defined by the width of the 95% confidence interval for this estimate, which is from 3.04 to 6.96 points. "),(0,a.Lk)("li",null," Given the fixed sample size, the investigator can be confident where the true value lies for the difference in FIM between standard and new rehabilitation program (somewhere between 3.04 and 6.96). Given that a clinically meaningful change in FIM score is 10 points, the observed between-group difference of 5 points suggests only a moderate improvement with the new program. The upper bound of the CI (6.96) suggests that even the largest plausible effect size value is still not clinically meaningful. ")])])],-1);function Bt(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[qt,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-3",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[Ot])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[Pt])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[Yt,Nt,Xt])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[Gt,jt])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var Ht={setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const Qt=(0,p.A)(Ht,[["render",Bt]]);var Kt=Qt;function Jt(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("p",null," Retrospective research implies starting with existing data on a cohort and examining past records to track outcomes, whereas prospective research begins with an identified cohort, and tracks outcomes moving forward in time. ")}var $t={};const Zt=(0,p.A)($t,[["render",Jt],["__scopeId","data-v-4aafbea3"]]);var en=Zt;const tn=(0,a.Lk)("p",null," Cases (individuals with the outcome of interest) and controls (those without the outcome) are identified, exposure status is determined for cases and controls retrospectively, and the baseline characteristics of cases and controls are compared to assess the association between exposure or intervention and outcome. ",-1),nn=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Efficiency"),(0,a.eW)(": Case-control studies are often more efficient than cohort studies, especially when studying rare outcomes. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Suitable for rare outcomes"),(0,a.eW)(": Ideal for investigating diseases or outcomes with low prevalence. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Cost-Effective"),(0,a.eW)(": Generally requires less time and resources than prospective cohort studies. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Multiple exposures"),(0,a.eW)(": Allows for the study of multiple exposures in relation to a single outcome. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Useful for hypothesis generation"),(0,a.eW)(": Effective for generating hypotheses or exploring associations that can be further investigated in more rigorous study designs. ")])],-1),an=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection of an appropriate control group"),(0,a.eW)(": Researchers need to carefully consider the characteristics of the control group in relation to the cases, taking steps to minimize bias and confounding and ensuring that the control group adequately represents the population from which the cases were drawn. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Recall bias"),(0,a.eW)(": Participants may have difficulty accurately recalling past exposures, particularly if the exposure occurred a long time ago. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Temporality challenges"),(0,a.eW)(": Establishing a clear temporal sequence between exposure and outcome can be challenging, as case-control studies are retrospective. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Not suitable for rare exposures"),(0,a.eW)(": If the exposure is rare, finding enough cases and controls with the exposure may be difficult. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection bias"),(0,a.eW)(": The process of selecting cases and controls may introduce bias if they are not representative of the population. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Cannot establish causation"),(0,a.eW)(": While useful for identifying associations, case-control studies alone cannot establish causation. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Dependence on existing data"),(0,a.eW)(": Relies on existing data or participants' recall of past exposures, which may be less accurate than prospective data collection. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Difficulty in determining exposure levels"),(0,a.eW)(": It may be challenging to determine the level or intensity of exposure accurately. ")])],-1),on=(0,a.Lk)("p",null," To critically appraise case-control studies, consider factors such as selection of controls, adequacy of data on exposure, adequate sample size to provide precise estimates, and use of validated and clinically relevant exposure measurement. There are several types of bias that can potentially impact equivalence or non-inferiority randomized clinical trials (RCTs). Here are the main types to consider. ",-1),sn=(0,a.Lk)("p",null," The impact of bias in the selection of cases and controls can cause the observed association to be either stronger or weaker than the true association. ",-1),ln=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection of controls"),(0,a.eW)(": Bias can occur if controls are not selected properly, meaning they do not represent the population that produced the cases. There are different types of biases in the selection of controls to consider. "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Berkson's Bias"),(0,a.eW)(": When cases and controls are selected from hospitalized patients, leading to a non-representative sample. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Control selection bias"),(0,a.eW)(": When controls are selected based on criteria related to the exposure, leading to bias. ")])])]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection of cases"),(0,a.eW)(": Bias can occur if cases are not selected properly, meaning they do not represent the population that produced the cases. There are different types of biases in the selection of cases to consider. "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Hospital patient selection bias"),(0,a.eW)(": Cases are selected from hospital patients, which may not represent the general population of cases. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Survivor bias"),(0,a.eW)(": Only cases who survived a condition are included, potentially excluding those with more severe disease who did not survive. ")])])]),(0,a.Lk)("li",null," The impact of bias in the selection of cases and controls can cause the observed association to be either stronger or weaker than the true association. "),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Recall bias"),(0,a.eW)(": Cases and controls may not remember their exposures accurately; cases may be more (or less) likely to accurately remember exposure leading to differential misclassification. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Interviewer bias"),(0,a.eW)(": If interviewers know the case/control status, they may probe differently for exposure information, introducing differential misclassification. ")])],-1),rn=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"3b"),(0,a.eW)(".")],-1),cn=(0,a.Lk)("p",null," Level 3 evidence is obtained from well-designed case-control or cohort studies. These studies usually involve comparing groups of individuals with a specific outcome (cases) to those without the outcome (controls) and investigating the potential exposure or risk factor retrospectively. ",-1),un=(0,a.Lk)("p",null," These studies provide moderate-quality evidence that is useful for identifying associations and generating hypotheses, especially for rare conditions. However, they are susceptible to various biases and cannot establish causality. When interpreting results from case-control studies, it is important to consider these limitations and use the findings as a basis for further research and higher-level evidence gathering. ",-1),dn=(0,a.Lk)("h4",{class:"my-4"}," Is there a significant association between smoking and the risk of developing lung cancer? ",-1),pn=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study design"),(0,a.eW)(": Case-Control Study")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study population"),(0,a.eW)(": "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Cases"),(0,a.eW)(": Patients diagnosed with lung cancer at the hospital between 2015 and 2020. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Controls"),(0,a.eW)(": Patients without lung cancer, matched by age and sex, who were treated at the same hospital for non-cancerous conditions during the same period. ")])])]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Independent Variables"),(0,a.eW)(": "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Exposure Measure"),(0,a.eW)(": Smoking status ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Exposed Group"),(0,a.eW)(": Individuals who have a history of smoking (current or former smokers). ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Non-Exposed Group"),(0,a.eW)(": Individuals who have never smoked. ")])])]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Outcome Measure"),(0,a.eW)(": Diagnosis of lung cancer (yes/no). ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Measure of Association"),(0,a.eW)(": Odds Ratio (OR). The odds ratio is a measure of association that quantifies the odds of exposure (smoking) among cases (lung cancer patients) relative to the odds of exposure among controls (patients without lung cancer). ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Data and Analysis"),(0,a.eW)(": "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Cases (Lung Cancer Patients)"),(0,a.eW)(": Smokers: 80, Non-Smokers: 20. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Controls (Non-Cancer Patients)"),(0,a.eW)(": Smokers: 40, Non-Smokers: 60 ")])])]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Odds Calculation"),(0,a.eW)(": "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Odds of Smoking among Cases"),(0,a.eW)(": 80/20 = 4 ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Odds of Smoking among Controls"),(0,a.eW)(": 40/60 = 2/3 ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Odds Ratio (OR)"),(0,a.eW)(": 6")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"95% Confidence Interval (CI) for the Odds Ratio"),(0,a.eW)(": 3.2 to 11.3 ")])])])],-1),hn=(0,a.Lk)("p",{className:"mt-5 pb-0"}," The odds of smoking among lung cancer patients are approximately 6 times higher than among patients without lung cancer. The 95% confidence interval for the OR ranges from 3.2 to 11.3, indicating a moderately precise estimate of the association between smoking and lung cancer. ",-1);function fn(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[tn,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-5",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[(0,a.eW)("Crticial Appraisal")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[nn])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[an])),_:1}),(0,a.bF)(xe.Y,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[on,sn,ln])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[rn,cn,un])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[dn,pn,hn])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var mn={setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const gn=(0,p.A)(mn,[["render",fn]]);var vn=gn;const bn=(0,a.Lk)("p",null," Observational research designs that collect data from participants at a single point in time, providing a snapshot of a population. They aim to examine the prevalence of exposure and outcome variables within the population and identify associations. Cross-sectional studies are often a starting point for research, guiding the development of more robust study designs to explore causal relationships. ",-1),kn=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Quick and relatively inexpensive"),(0,a.eW)(": Cross-sectional studies are relatively quick and cost-effective compared to longitudinal studies, as they gather data at a single point in time. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Provides a snapshot of the population"),(0,a.eW)(": These studies give an overview of a population's characteristics at a specific time, providing insights into the prevalence of exposure and outcome variables. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Useful for generating hypotheses"),(0,a.eW)(": Cross-sectional studies are often the first step in research, allowing researchers to generate hypotheses for further investigation. ")])],-1),yn=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Limited causal inference"),(0,a.eW)(": Cross-sectional designs focus on associations rather than causal relationships. It is challenging to establish the direction of causality or determine if the exposure preceded the outcome. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Potential for selection bias"),(0,a.eW)(": Cross-sectional studies may suffer from selection bias if the participants are not representative of the target population, leading to results that are not generalizable. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Recall bias and measurement error"),(0,a.eW)(": As data are collected at a single time point, participants' recall of past exposures and outcomes may be inaccurate, leading to recall bias and measurement error in the study. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Nonresponse bias"),(0,a.eW)(": If participation rates are low, those who choose to participate may differ systematically from those who don't, introducing nonresponse bias. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Cross-sectional bias"),(0,a.eW)(": Bias may arise from comparing respondents' characteristics at a single point in time, potentially leading to biased associations or misleading conclusions. ")])],-1),Ln=(0,a.Lk)("p",null," To critically appraise cross-sectional studies, consider factors such as selection of study participants and adequacy of data, and take care to avoid bias in assessing exposure to on exposure. ",-1),wn=(0,a.Lk)("p",null," There are several types of bias that can potentially impact cross-sectional studies: ",-1),Wn=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection bias"),(0,a.eW)(": Selection bias can occur if the selection of study participants is not representative of the target population. This bias can lead to an over- or underrepresentation of certain groups, which can affect the generalizability of the study findings. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Information bias"),(0,a.eW)(": Information bias can occur if there are errors or inaccuracies in the data collected. It can arise due to self-reporting by participants or limitations in the measurement tools used to assess exposures or outcomes. If there is differential misclassification of exposure or outcome between comparison groups, it can introduce bias into the study results. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Observer bias"),(0,a.eW)(": Observer bias can occur if the researchers collecting the data are aware of the participants' exposure status and this knowledge influences how the data is collected or recorded. ")])],-1),xn=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"2c"),(0,a.eW)(".")],-1),Cn=(0,a.Lk)("p",null,' Level 2c, specifically applied to cross-sectional studies, signifies a moderate level of evidence. The letter "C" represents cross-sectional studies within Level 2 evidence. ',-1),_n=(0,a.Lk)("p",null," While cross-sectional studies provide valuable insights into associations, they have limitations in terms of establishing causality and addressing biases. Therefore, they are considered moderate-level evidence and provide a less robust level of evidence compared to higher-ranking levels, such as randomized controlled trials (RCTs) or systematic reviews/meta-analyses. ",-1),Sn=(0,a.Lk)("h4",{class:"my-4"}," What is the relationship between physical activity levels and mental health outcomes in college students? ",-1),Fn=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study design"),(0,a.eW)(": A cross-sectional study design will be employed, where data will be collected at a single point in time from a representative sample of college students. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study Population"),(0,a.eW)(": The study will include undergraduate students from various universities across the country, aged 18-25 years, who are currently enrolled in full-time programs. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Variables"),(0,a.eW)(": The variables of interest will include physical activity level (measured using validated questionnaires), mental health outcomes (measured using standardized scales), age, gender, body mass index (BMI), academic performance, and socioeconomic status. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Primary Results"),(0,a.eW)(": The study will aim to explore the association between physical activity levels and mental health outcomes. Possible results may include finding a significant positive correlation between higher physical activity levels and better mental health outcomes in college students. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample size calculation"),(0,a.eW)(": Assuming a power of 0.80, alpha level of 0.05, and an expected moderate effect size based on prior studies, a sample size of 400 participants may be required. ")])],-1);function Tn(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[bn,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-5",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[(0,a.eW)("Crticial Appraisal")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[kn])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[yn])),_:1}),(0,a.bF)(xe.Y,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[Ln,wn,Wn])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[xn,Cn,_n])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[Sn,Fn])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var zn={setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const En=(0,p.A)(zn,[["render",Tn]]);var An=En;function Mn(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("p",null," Descriptive studies are not hypothesis-driven and aim to characterize and document. The purpose is to explore patterns, identify trends, or generate hypotheses. ")}var Rn={};const In=(0,p.A)(Rn,[["render",Mn],["__scopeId","data-v-4112b1e0"]]);var Dn=In;function Un(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("p",null," Studies with one subject focus on a detailed examination of a single patient, while those with multiple subjects observe trends and patterns. ")}var Vn={};const qn=(0,p.A)(Vn,[["render",Un],["__scopeId","data-v-54d0e0ad"]]);var On=qn;const Pn=(0,a.Lk)("p",null," Case reports involve the detailed documentation and analysis of the clinical characteristics, diagnostic findings, treatment approaches, and outcomes of individual patients with unique or rare medical conditions, unusual presentations, or unexpected outcomes. They typically provide a narrative description of the patient's medical history and relevant information. Case reports are a form of anecdotal evidence and contribute to the medical literature by sharing valuable clinical experiences. ",-1),Yn=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Unique or rare cases"),(0,a.eW)(": Case reports provide an opportunity to examine and document unusual or rare medical conditions, which can contribute to medical knowledge and understanding of these conditions. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Valuable clinical experiences"),(0,a.eW)(": Case reports share valuable clinical experiences and provide insights into diagnostic challenges, treatment approaches, and unexpected outcomes. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Hypothesis generation"),(0,a.eW)(": Case reports can help generate hypotheses for future research by highlighting associations or patterns that warrant further investigation. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Educational value"),(0,a.eW)(": Case reports serve as teaching tools for medical education, allowing healthcare professionals to learn from real-world clinical scenarios. ")])],-1),Nn=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Limited generalizability"),(0,a.eW)(": Due to the nature of case reports focusing on individual cases, their findings cannot be easily generalized to a larger population. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Lack of control group"),(0,a.eW)(": Case reports lack a comparison group or control, making it difficult to establish causality or determine the true effectiveness of a treatment. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Bias and subjectivity"),(0,a.eW)(": Case reports can be influenced by various biases, including reporting bias, confirmation bias, and observer bias. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Lack of statistical analysis"),(0,a.eW)(": Case reports often lack statistical analysis, making it challenging to assess the statistical significance of the reported outcomes. ")])],-1),Xn=(0,a.Lk)("p",null," To critically appraise case reports, consider factors such as selective reporting of details, preconceived notions about a particular condition, and researcher’s own bias. There are several types of bias that can potentially impact cross-sectional studies: ",-1),Gn=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Reporting bias"),(0,a.eW)(": Case reports may be influenced by the selective reporting of specific details, omitting certain information that does not align with the desired outcome or conclusion. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Confirmation bias"),(0,a.eW)(": Researchers may have preconceived notions or beliefs about a particular condition or treatment, leading to a biased interpretation of the case details. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Observer bias"),(0,a.eW)(": The researcher's own biases and expectations can influence the documentation and interpretation of the case, potentially leading to subjective assessments. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Publication bias"),(0,a.eW)(": Case reports with more extraordinary or positive outcomes are more likely to be published, leading to an overemphasis on exceptional cases and potentially creating a skewed representation of reality. ")])],-1),jn=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"4"),(0,a.eW)(".")],-1),Bn=(0,a.Lk)("p",null," Level 4 evidence refers to case reports or case series that provide anecdotal or descriptive information about individual cases or a series of cases. Level 4 evidence is considered the lowest level of evidence on the hierarchy. ",-1),Hn=(0,a.Lk)("p",null," While case reports can contribute to the medical literature by sharing valuable clinical experiences and observations, they are considered anecdotal evidence and have inherent limitations. This level of evidence does not involve systematic data collection or comparison with control groups, making it difficult to establish causality or generalize to a broader population. ",-1),Qn=(0,a.Lk)("p",null," The findings in case reports are based on individual experiences and can be influenced by reporting bias, confirmation bias, and other types of bias. ",-1),Kn=(0,a.Lk)("h4",{class:"my-4"}," What is the impact of virtual reality therapy on anxiety levels in pediatric patients? ",-1),Jn=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study design"),(0,a.eW)(": Case series report")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study population"),(0,a.eW)(": Pediatric patients aged 8 to 12 years, diagnosed with anxiety disorders, and seeking treatment at a pediatric mental health clinic. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Suggested variables"),(0,a.eW)(": "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Independent Variable"),(0,a.eW)(": Virtual Reality Therapy (VRT), Exposure to VR therapy sessions, Duration of each VR therapy session, and Specific VR environments used ")]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Dependent Variable"),(0,a.eW)(": Anxiety Levels - Measured using a validated anxiety scale before and after VRT sessions ")])])]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample Size Calculation"),(0,a.eW)(": Given the exploratory nature of the case series design and the absence of a predetermined sample size calculation, our study aimed to include a convenience sample of pediatric patients who meet the inclusion criteria and consent to participate in the VRT program. As we gather data from these cases, we will compile and analyze the results to provide descriptive information about the impact of VRT on anxiety levels in pediatric patients. ")])],-1);function $n(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[Pn,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-5",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[(0,a.eW)("Crticial Appraisal")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[Yn])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[Nn])),_:1}),(0,a.bF)(xe.Y,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[Xn,Gn])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[jn,Bn,Hn,Qn])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[Kn,Jn])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var Zn={setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const ei=(0,p.A)(Zn,[["render",$n]]);var ti=ei;const ni=(0,a.Lk)("p",null," A descriptive study design that involves the detailed analysis of a group of patients with similar characteristics or who share a common condition. Provides a comprehensive and in-depth description of the clinical characteristics, course of disease, and outcomes for the patients included in the series. Unlike experimental designs, case series lack a comparison group for assessing causation. ",-1),ii=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Rich clinical information"),(0,a.eW)(": Case series reports allow for in-depth characterization of individual cases, providing valuable clinical information and expanding knowledge in specific fields. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Hypothesis generation"),(0,a.eW)(": They can generate hypotheses and identify potential associations or outcomes that need further investigation through more rigorous study designs. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Rare conditions or events"),(0,a.eW)(": Case series provide a means to study rare conditions or events where randomized controlled trials may not be feasible or ethical. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Clinical insights"),(0,a.eW)(": Provides valuable clinical insights and contributes to the understanding of disease patterns, natural history, and potential treatment approaches. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Illustrative Cases"),(0,a.eW)(": Illustrative cases within a series can be used for educational purposes, enhancing medical knowledge and training. ")])],-1),ai=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Lack of comparison or control group"),(0,a.eW)(": The absence of a comparison or control group limits the ability to establish causality or differentiate between the effects of the intervention and other factors. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Inherent selection bias"),(0,a.eW)(": The selection of cases for inclusion in the series is often based on certain criteria, which may result in a non-representative sample and introduce bias. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Limited generalizability"),(0,a.eW)(": Findings from case series reports cannot be generalized to the broader population due to the absence of randomization and control. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Critical Appraisal"),(0,a.eW)(": To critically appraise case reports, consider factors such as selective reporting of details, preconceived notions about a particular condition, and researcher’s own bias. There are several types of bias that can potentially impact cross-sectional studies. Here are the main types to consider. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Ascertainment bias"),(0,a.eW)(": Cases may be selected based on certain characteristics or circumstances, leading to an unrepresentative sample. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Reporting bias"),(0,a.eW)(": Variations in reporting practices and inconsistent documentation may introduce biases in data collection. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Observer bias"),(0,a.eW)(": Researchers or clinicians involved in collecting and interpreting data may introduce their own subjective biases. ")])],-1),oi=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"4"),(0,a.eW)(".")],-1),si=(0,a.Lk)("p",null," Level 4 evidence refers to case reports or case series that provide anecdotal or descriptive information about individual cases or a series of cases. Level 4 evidence is considered the lowest level of evidence on the hierarchy. ",-1),li=(0,a.Lk)("p",null," While case series can contribute to the medical literature by sharing valuable clinical experiences and observations, they are considered anecdotal evidence and have inherent limitations. This level of evidence does not involve systematic data collection or comparison with control groups, making it difficult to establish causality or generalize to a broader population. ",-1),ri=(0,a.Lk)("p",null," Case series reports contribute exploratory evidence and can be useful for generating hypotheses, but they require further research with more rigorous designs to establish stronger evidence. ",-1),ci=(0,a.Lk)("h4",{class:"my-4"}," What is the impact of mindfulness practices on stress reduction in college students? ",-1),ui=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study design"),(0,a.eW)(": Case series report")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study population"),(0,a.eW)(": College students aged 18-25 years, enrolled in a university setting, and experiencing elevated levels of stress. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Suggested variables"),(0,a.eW)(": "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Independent Variable"),(0,a.eW)(": Mindfulness Practices "),(0,a.Lk)("ul",null,[(0,a.Lk)("li",null," Type of mindfulness practice (e.g. meditation, deep breathing exercises, yoga) "),(0,a.Lk)("li",null," Frequency and duration of mindfulness practice sessions "),(0,a.Lk)("li",null," Specific techniques used within mindfulness practices ")])]),(0,a.Lk)("li",null,[(0,a.Lk)("span",{class:"italic"},"Dependent Variable"),(0,a.eW)(": Stress Levels - Measured using a validated stress scale before and after practicing mindfulness techniques ")])])]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample size calculation"),(0,a.eW)(": For this case series report, a convenient sample of college students who meet the inclusion criteria and consent to participate in the mindfulness program will be recruited. While there is no predetermined sample size calculation, the aim is to include an adequate number of cases to provide descriptive information about the impact of mindfulness practices on stress reduction in college students. The final sample size will depend on the number of eligible participants who complete the study. ")])],-1);function di(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[ni,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-5",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[ii])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[ai])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[oi,si,li,ri])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[ci,ui])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var pi={setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const hi=(0,p.A)(pi,[["render",di]]);var fi=hi;function mi(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("p",null," A crucial requirement in assessing the relationship between an exposure or intervention and an outcome. The comparison group consists of individuals or a cohort of participants who do not have the exposure or intervention of interest, allowing for a comparison with those who do. The lack of a comparison group makes it challenging to draw conclusions about the effectiveness of a particular treatment or the causal relationship between an exposure and outcome. ")}var gi={};const vi=(0,p.A)(gi,[["render",mi],["__scopeId","data-v-120f8376"]]);var bi=vi;const ki=e=>((0,a.Qi)("data-v-0ba3e0f3"),e=e(),(0,a.jt)(),e),yi=ki((()=>(0,a.Lk)("p",{class:"pb-5"}," In an observational study, the investigator does not control or assign exposure. Instead, they observe and analyze existing exposures or interventions that occur naturally, without any interference. Observational studies are often used to study associations, trends, or the natural course of diseases. ",-1))),Li=ki((()=>(0,a.Lk)("p",null," For example, a researcher conducts a cohort study to investigate the association between smoking and lung cancer. The researcher observes individuals over time, categorizes them based on their smoking status, and analyzes the incidence of lung cancer. ",-1)));function wi(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)(a.FK,null,[yi,Li],64)}var Wi={};const xi=(0,p.A)(Wi,[["render",wi],["__scopeId","data-v-0ba3e0f3"]]);var Ci=xi;function _i(e,t){return(0,a.uX)(),(0,a.CE)("p",null," In these cases, the research question focuses on establishing the superiority of one treatment over another in terms of effectiveness or outcomes. ")}const Si={},Fi=(0,p.A)(Si,[["render",_i]]);var Ti=Fi;const zi=(0,a.Lk)("p",null," A superiority trial aims to show that one treatment is significantly better than another in terms of efficacy, safety, or both. It is a specific type of randomized clinical trial designed to establish that a new intervention or treatment is superior to an existing one. Researchers hypothesize that the new intervention will be more effective, safer, or have better outcomes compared to the existing intervention or control group. ",-1),Ei=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Relevant assessment"),(0,a.eW)(": These trials address clinically important questions by comparing treatments that are expected to have similar effectiveness. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Practicality"),(0,a.eW)(": Conducting an equivalence or non-inferiority trial can be more feasible when demonstrating superiority is unlikely or unethical. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Broader options"),(0,a.eW)(": Establishing non-inferiority allows physicians and patients to consider alternative treatment options that may have other benefits (e.g., cost, convenience) while still maintaining acceptable efficacy. ")])],-1),Ai=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Challenging design"),(0,a.eW)(": It can be complex to determine an appropriate non-inferiority margin, which defines the acceptable difference between treatments. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Risk of false conclusions"),(0,a.eW)(": If the non-inferiority margin is set too wide or the study lacks statistical power, the trial may fail to detect a clinically relevant difference between treatments, leading to a false conclusion of non-inferiority. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Interpretation of results"),(0,a.eW)(": Demonstrating non-inferiority does not establish the new treatment's superiority; it only establishes that it is not worse beyond the predefined margin. ")])],-1),Mi=(0,a.Lk)("p",null," To critically appraise equivalence or non-inferiority RCTs, consider factors such as adequacy of randomization, use of blinding, adequate sample size to provide precise estimates, and use of validated and clinically relevant outcome measurement. There are several types of bias that can potentially impact equivalence or non-inferiority randomized clinical trials (RCTs). Here are the main types to consider. ",-1),Ri=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Measurement bias"),(0,a.eW)(": Biases in measuring outcomes or assessing comparability between treatments can affect the comparison of effectiveness. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Non-Adherence bias"),(0,a.eW)(": Differences in adherence to treatment protocols can impact the efficacy comparison between groups. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Reporting bias"),(0,a.eW)(": Selective reporting or incomplete reporting of outcomes can introduce bias in favor of one treatment over the other. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Attrition bias"),(0,a.eW)(": If participant dropout rates differ between treatment groups and are related to treatment effectiveness, it can bias the assessment of equivalence or non-inferiority. ")])],-1),Ii=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"2b"),(0,a.eW)(".")],-1),Di=(0,a.Lk)("p",null," Level 2b evidence refers to trials that address the comparative effectiveness of treatments, interventions, or diagnostic tests. These trials aim to determine if the new treatment is not worse than the comparator treatment by more than a pre-defined non-inferiority margin. Even if the new treatment does not demonstrate superiority, if it falls within the pre-defined margin, it is considered clinically equivalent or non-inferior. ",-1),Ui=(0,a.Lk)("h4",{class:"my-4"}," Is treatment X (e.g., a novel medication targeting a specific receptor) for chronic pain non-inferior to the current standard treatment (e.g., a combination of pain-relief medications and lifestyle modifications) in terms of reducing pain and improving functional status in patients with chronic migraine? ",-1),Vi=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study design"),(0,a.eW)(": Randomized controlled non-inferiority trial ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study population"),(0,a.eW)(": Adults (age 18-65) diagnosed with chronic migraine, who meet the inclusion and exclusion criteria and are willing to participate. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Dependent variables"),(0,a.eW)(": Pain severity and frequency, functional status (e.g., ability to perform daily activities), and safety profiles. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Duration of follow-up"),(0,a.eW)(": 12 weeks")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Primary outcome measure"),(0,a.eW)(": Reduction in pain severity from baseline to week 12, measured using a validated pain scale. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Clinically meaningful difference"),(0,a.eW)(": The non-inferiority margin of 20% difference in pain reduction has been determined to be clinically acceptable, indicating that treatment X should not be more than 20% worse than the current standard treatment in terms of reducing pain severity. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample size calculation"),(0,a.eW)(": Assuming a predetermined non-inferiority margin of a 20% difference in pain reduction, with a two-sided significance level of 0.05 and a statistical power of 80%, a sample size calculation estimates a minimum of 250 participants (125 per group). ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Margin of non-inferiority"),(0,a.eW)(": The margin of non-inferiority refers to the predefined difference in treatment effect that is considered clinically acceptable. In this fictional trial, a 20% difference in pain reduction is determined to be the margin of non-inferiority, indicating that treatment X will be considered non-inferior if it is not worse than the current standard treatment by more than 20% in terms of pain reduction. ")])],-1);function qi(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[zi,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-3",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[(0,a.eW)("Cricial Appraisal")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[Ei])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[Ai])),_:1}),(0,a.bF)(xe.Y,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[Mi,Ri])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[Ii,Di])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[Ui,Vi])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var Oi={setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const Pi=(0,p.A)(Oi,[["render",qi]]);var Yi=Pi;const Ni=(0,a.Lk)("p",null," A superiority trial aims to show that one treatment is significantly better than another in terms of efficacy, safety, or both. It is a specific type of randomized clinical trial designed to establish that a new intervention or treatment is superior to an existing one. Researchers hypothesize that the new intervention will be more effective, safer, or have better outcomes compared to the existing intervention or control group. ",-1),Xi=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Clear objective"),(0,a.eW)(": The primary objective of superiority trials is to determine if one treatment is significantly better than another, providing a clear and specific research aim. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"High scientific rigor"),(0,a.eW)(": Superiority trials are usually designed with strict methodology, including randomization, blinding, and control groups, which enhances the internal validity of the study. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Direct clinical relevance"),(0,a.eW)(": Successful demonstration of superiority can have immediate clinical implications, allowing for evidence-based decision-making in treatment selection. ")])],-1),Gi=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"High sample size requirements"),(0,a.eW)(": Superiority trials typically require large sample sizes to achieve adequate statistical power, which can be resource-intensive, time-consuming, and potentially costly. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Ethical considerations"),(0,a.eW)(": The requirement of a control group with placebo or standard therapy may raise ethical concerns due to withholding potentially effective treatments from participants. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Dependent on patient compliance"),(0,a.eW)(": The validity of superiority trials heavily relies on participant compliance with assigned treatments, which may vary and introduce potential bias. ")])],-1),ji=(0,a.Lk)("p",{class:"mb-5"}," To critically appraise superiority RCTs, consider factors such as adequacy of randomization, use of blinding, adequate sample size to provide precise estimates, and use of validated and clinically relevant outcome measurements. There are several types of bias that can potentially impact superiority randomized clinical trials (RCTs). Here are the main types to consider. ",-1),Bi=(0,a.Lk)("ol",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Selection bias"),(0,a.eW)(": This bias can occur if there is a systematic difference in the characteristics of participants assigned to different treatment groups. For example, if the randomization process fails to properly balance important factors between the groups, it can introduce bias and affect the validity of the trial results. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Performance bias"),(0,a.eW)(": This bias can arise when participants or care providers are aware of the assigned treatments, which may influence their behavior or decision-making during the trial. To mitigate this bias, blinding or masking techniques are often employed to maintain participant and/or provider unawareness of the assigned treatments. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Detection bias"),(0,a.eW)(": Also known as ascertainment bias or observer bias, this occurs when outcome assessors are influenced by their knowledge of the treatment group assignments, leading to biased assessment or interpretation of outcomes. Blinding assessors to treatment allocation can help minimize this bias. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Attrition bias"),(0,a.eW)(": This bias occurs when participants drop out from the study, and their reasons for dropping out may be related to their treatment or outcome status, resulting in incomplete or biased data. High attrition rates can impact the generalizability of the findings and introduce bias if not appropriately addressed. ")])],-1),Hi=(0,a.Lk)("h4",{class:"my-4"},[(0,a.eW)("Level of Evidence "),(0,a.Lk)("strong",null,"1b"),(0,a.eW)(".")],-1),Qi=(0,a.Lk)("p",null," Level 1b evidence refers to evidence derived from well-conducted randomized clinical trials (RCTs) with a narrow confidence interval. In Level 1b evidence, the research is based on high-quality RCTs that include appropriate randomization methods and have controlled for biases effectively. These trials often involve enough participants to provide statistical power for drawing reliable conclusions. The narrow confidence interval indicates a precise estimation of the treatment effect, reducing uncertainty. ",-1),Ki=(0,a.Lk)("p",null," Level 1b evidence is among the highest levels of evidence available. It provides valuable information on the effectiveness of interventions, treatments, or therapies, offering robust evidence for clinical decision-making. ",-1),Ji=(0,a.Lk)("h4",{class:"my-4"}," Is the new immunotherapy drug superior to methotrexate, the current standard treatment in improving clinical outcomes in patients with rheumatoid arthritis? ",-1),$i=(0,a.Lk)("ul",null,[(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study design"),(0,a.eW)(": Randomized controlled trial (RCT) ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Study population"),(0,a.eW)(": Adults (age 18-65) diagnosed with rheumatoid arthritis, who meet the inclusion and exclusion criteria for the trial and are willing to participate. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Dependent variables"),(0,a.eW)(": Clinical outcomes specific to condition Y, such as symptom severity, functional status, or quality of life. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Duration of follow-up"),(0,a.eW)(": 24 weeks")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Primary outcome measure"),(0,a.eW)(': Improvement in symptom severity score from baseline to week 24, measured using the "Patient Global Assessment of Disease Activity" (PGA). The PGA is a patient-reported outcome measure where patients rate their overall disease activity on a numerical scale or using verbal descriptors. ')]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Clinically meaningful difference"),(0,a.eW)(": Studies suggest that a change of at least 1 point on the 0-10 numerical scale of the PGA represents a clinically meaningful difference in disease activity. ")]),(0,a.Lk)("li",null,[(0,a.Lk)("strong",null,"Sample size calculation"),(0,a.eW)(": Assuming a two-sided significance level of 0.05 and a statistical power of 80%, previous research has suggested that clinically meaningful improvement in the symptom severity score is a change of at least 1 point on the PGA. With this information, a sample size calculation estimates a minimum of 100 participants (50 in each group) based on anticipated effect sizes and variability. ")])],-1);function Zi(e,t,n,i,o,s){return(0,a.uX)(),(0,a.CE)("div",null,[Ni,(0,a.bF)(y.J,{class:"mt-5"},{default:(0,a.k6)((()=>[(0,a.bF)(Le.h,{modelValue:i.tab,"onUpdate:modelValue":t[0]||(t[0]=e=>i.tab=e),"bg-color":"gray",grow:"",class:"mb-3",direction:i.isMobile?"vertical":"horizontal"},{default:(0,a.k6)((()=>[(0,a.bF)(we.U,{value:"strengths"},{default:(0,a.k6)((()=>[(0,a.eW)("Strengths")])),_:1}),(0,a.bF)(we.U,{value:"weaknesses"},{default:(0,a.k6)((()=>[(0,a.eW)("Weaknesses")])),_:1}),(0,a.bF)(we.U,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[(0,a.eW)("Cricial Appraisal")])),_:1}),(0,a.bF)(we.U,{value:"oxford"},{default:(0,a.k6)((()=>[(0,a.eW)("Oxford CEBM Level of Evidence")])),_:1}),(0,a.bF)(we.U,{value:"example"},{default:(0,a.k6)((()=>[(0,a.eW)("Example Study")])),_:1})])),_:1},8,["modelValue","direction"]),(0,a.bF)(We.l,{modelValue:i.tab,"onUpdate:modelValue":t[1]||(t[1]=e=>i.tab=e)},{default:(0,a.k6)((()=>[(0,a.bF)(xe.Y,{value:"strengths"},{default:(0,a.k6)((()=>[Xi])),_:1}),(0,a.bF)(xe.Y,{value:"weaknesses"},{default:(0,a.k6)((()=>[Gi])),_:1}),(0,a.bF)(xe.Y,{value:"criticalAppraisal"},{default:(0,a.k6)((()=>[ji,Bi])),_:1}),(0,a.bF)(xe.Y,{value:"oxford"},{default:(0,a.k6)((()=>[Hi,Qi,Ki])),_:1}),(0,a.bF)(xe.Y,{value:"example"},{default:(0,a.k6)((()=>[Ji,$i])),_:1})])),_:1},8,["modelValue"])])),_:1})])}var ea={name:"RandomizedControlledTrialDescription",setup(){const{windowWidth:e,isMobile:t}=Ee();(0,a.Gt)("windowWidth",e),(0,a.Gt)("isMobile",t);const n=(0,ze.KR)(0);return{windowWidth:e,isMobile:t,tab:n}}};const ta=(0,p.A)(ea,[["render",Zi]]);var na=ta,ia={AssignExposures:ye,RandomAllocationDescription:Re,ExperimentalStudyDescription:Ve,RandomizedControlledTrialDescription:$e,NonRandomizedControlledTrialDescription:ht,AnalyticalStudyDescription:vt,DirectionDescription:_t,ProspectiveCohortStudyDescription:Vt,RetrospectiveCohortStudyDescription:Kt,PerspectiveQuestion:en,CaseControlStudyDescription:vn,CrossSectionalStudyDescription:An,DescriptiveStudyDescription:Dn,HowManySubjctsDescription:On,CaseReportDescription:ti,CaseSeriesDescription:fi,ComparisonGroupDescription:bi,ObservationalStudyDescription:Ci,NewTreatmentBetter:Ti,EquivalenceTrial:Yi,SuperiorityTrial:na},aa=n(79669),oa=n(76938),sa=n(84117),la=n(4913),ra=n(38225);function ca(e,t,n,i,o,s){return(0,a.uX)(),(0,a.Wv)(ra.q,null,{activator:(0,a.k6)((({props:e})=>[(0,a.bF)(aa.w,(0,a.v6)({icon:"mdi-dots-horizontal"},e),null,16)])),default:(0,a.k6)((()=>[(0,a.bF)(oa.x8,null,{default:(0,a.k6)((()=>[((0,a.uX)(!0),(0,a.CE)(a.FK,null,(0,a.pI)(o.items,((i,o)=>((0,a.uX)(),(0,a.Wv)(sa.g,{onClick:t[0]||(t[0]=t=>e.$router.push({name:"FlowChart",query:{step:n.stepId}})),key:o,value:o},{default:(0,a.k6)((()=>[(0,a.bF)(la.U,null,{default:(0,a.k6)((()=>[(0,a.eW)((0,T.v_)(i.title),1)])),_:2},1024)])),_:2},1032,["value"])))),128))])),_:1})])),_:1})}var ua={props:["stepId"],data(){return{items:[{title:"View this step in flow chart"}]}}};const da=(0,p.A)(ua,[["render",ca]]);var pa=da,ha={props:["step"],data(){return{currentStep:N,path:[],steps:fe,nextStep:void 0}},components:{StepCard:Y,DropdownMenu:pa,...ia},watch:{currentStep(e,t){e!==t&&this.$router.push({path:"/decision-tree",query:{step:e}}).catch(console.error)}},created(){this.step&&fe[this.step]?this.step&&(this.currentStep=this.step,this.path=ge(this.steps[this.currentStep].inputs[0])):this.currentStep=N},computed:{currentQuestion(){return this.steps[this.currentStep]},breadcrumbs(){return[...this.path.map((e=>this.steps[e])),this.steps[this.currentStep]].filter((e=>"statement"===e.type))},progress(){let e=me(this.currentStep,this.steps),t=e+this.path.length,n=this.path.length;return n/t*100}},methods:{advanceTree(){this.path.push(this.currentStep),this.currentStep=this.nextStep,this.nextStep=void 0},setNextStep(e){this.nextStep=e},startOver(){this.currentStep=this.path[0],this.path=[],this.nextStep=void 0},goBack(){this.currentStep=this.path.pop(),this.nextStep=void 0}}};const fa=(0,p.A)(ha,[["render",V],["__scopeId","data-v-21076e6b"]]);var ma=fa;const ga=(0,a.Lk)("div",{class:"svg-container",id:"flowchart-container"},[(0,a.Lk)("svg",{class:"svg-content"},[(0,a.Lk)("g")])],-1);function va(e,t,n,i,o,s){return(0,a.uX)(),(0,a.Wv)(y.J,{class:"mx-auto my-12 container",elevation:2},{default:(0,a.k6)((()=>[(0,a.bF)(w.r,null,{default:(0,a.k6)((()=>[(0,a.eW)("Visual Decision Tree")])),_:1}),(0,a.bF)(L.m,null,{default:(0,a.k6)((()=>[ga])),_:1})])),_:1})}var ba=n(52478),ka=n(92119),ya=n(82883);function La(e){var t=ba.Ltv(e.node().parentNode),n=parseInt(e.style("width")),i=parseInt(e.style("height")),a=n/i;function o(){var n=parseInt(t.style("width"));e.attr("width",n),e.attr("height",Math.round(n/a))}e.attr("viewBox","0 0 "+n+" "+i).attr("perserveAspectRatio","xMinYMid").call(o),ba.Ltv(window).on("resize."+t.attr("id"),o)}const wa=e=>{ba.Ubm(".edgeLabel").each((function(t){var n=ba.Ltv(this);const{w:i}=t;var a=n.node().getBBox();n.insert("rect",":first-child").attr("x",a.x-2).attr("y",a.y-2).attr("width",a.width+4).attr("height",a.height+4).style("fill","#ffffff"),n.classed("previousStep",e.includes(i))}))},Wa=e=>{ba.Ubm(".edgePath").each((function(t){var n=ba.Ltv(this);const{w:i}=t;n.classed("previousStep",e.includes(i))}))};function xa(e,t){const{id:n,color:i}=e;let a=n===t?"currentStep":"";const o=fe[t]?ge(fe[t].id):[];return o.includes(n)?`${a} previousStep ${i}`:a}function Ca(e){const{color:t}=e;let n="";return`${n} ${t}`}var _a={name:"visual-flow-chart",props:["step"],data(){return{gdata:null,scale:1,graph:null}},created(){let e=new Map,t=Object.values(fe).map((e=>(e={...e,cssClass:this.step&&fe[this.step]?xa(e,this.step):Ca(e)},!e.choices&&e.next?{...e,choices:[{next:e.next}]}:e.choices||e.next?e:{...e,choices:[]})));for(const n in t){const{id:i,title:a,flowChartTitle:o,choices:s,detail:l,inputs:r,cssClass:c}=t[n];e.set(i,{title:o||a,choices:s,detail:l,inputs:r,cssClass:c})}this.gdata=e},mounted(){this.render()},methods:{render:function(){const e=this.$router;if(null===this.gdata)return"no data";const t=new ya.graphlib.Graph({}).setGraph({});for(const[s,l]of this.gdata.entries())t.setNode(s,{label:l.title,choices:l.choices,detail:l.detail,class:l.cssClass}),l.choices.forEach((e=>{t.setEdge(s,e.next,{arrowhead:"normal",curve:ba.qrM,label:e.answer})}));const n=ba.Ltv("div#flowchart-container").select("svg").attr("width",1320).attr("height",800).call(La),i=new ya.render;i(n,t);const a=ge(this.step);a.length&&n.classed("selectionMode",!0),wa(a),Wa(a);let o=ba.Ltv("body").append("div").attr("id","tooltip_template");n.selectAll("g.node").attr("data-detail",(e=>t.node(e).detail)).on("mouseenter",(()=>{this.dataset&&this.dataset.detail&&o.style("visibility","visible")})).on("click",(function(t){n.remove(),o.remove(),e.push({path:"decision-tree",query:{step:t}})})).on("mousemove",(function(){this.dataset.detail&&o.text(this.dataset.detail).style("top",event.pageY-10+"px").style("left",event.pageX+10+"px")})).on("mouseout",(()=>{ba.Ubm("rect.label-container").classed("parent",!1),ba.Ubm("rect.label-container").classed("child",!1),ba.Ubm("rect.label-container").classed("selected",!1),o.style("visibility","hidden")})).selectAll("rect.label-container").on("mouseenter",(function(){ba.Ltv(this).classed("selected",!0)})).on("mouseout",(function(){ba.Ltv(this).classed("selected",!1)})),ka.layout(t)},highlightEdges:function(e){let t=this.gdata.get(e).choices.map((e=>e.next)),n=this.gdata.get(e).inputs;function i(e,t){ba.Ltv("svg").selectAll("g.node").filter(e).select("rect.label-container").classed(t,!0)}t.length>0&&i((e=>t.includes(e)),"child");const a=t.filter((e=>n.includes(e)));n.length>0&&i((e=>n.includes(e)),"parent"),a.length>0&&i((e=>a.includes(e)),"parnet")}}};const Sa=(0,p.A)(_a,[["render",va]]);var Fa=Sa;const Ta=[{path:"/intro",name:"IntroMessage",component:F},{path:"/decision-tree",name:"DecisionTree",props:e=>({step:e.query.step}),component:ma},{path:"/flow-chart",name:"FlowChart",props:e=>({step:e.query.step}),component:Fa},{path:"/",redirect:"/intro"},{path:"/:catchAll(.*)",redirect:"/intro"}],za=(0,b.aE)({history:(0,b.LA)("/clinical-research-study-design/"),routes:Ta});var Ea=za,Aa=n(79968);v();let Ma=(0,i.Ef)(f);Ma.use(Aa.A),Ma.use(g),Ma.use(Ea),Ma.mount("#app")}},t={};function n(i){var a=t[i];if(void 0!==a)return a.exports;var o=t[i]={id:i,loaded:!1,exports:{}};return e[i].call(o.exports,o,o.exports,n),o.loaded=!0,o.exports}n.m=e,function(){var e=[];n.O=function(t,i,a,o){if(!i){var s=1/0;for(u=0;u<e.length;u++){i=e[u][0],a=e[u][1],o=e[u][2];for(var l=!0,r=0;r<i.length;r++)(!1&o||s>=o)&&Object.keys(n.O).every((function(e){return n.O[e](i[r])}))?i.splice(r--,1):(l=!1,o<s&&(s=o));if(l){e.splice(u--,1);var c=a();void 0!==c&&(t=c)}}return t}o=o||0;for(var u=e.length;u>0&&e[u-1][2]>o;u--)e[u]=e[u-1];e[u]=[i,a,o]}}(),function(){n.n=function(e){var t=e&&e.__esModule?function(){return e["default"]}:function(){return e};return n.d(t,{a:t}),t}}(),function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(i,a){if(1&a&&(i=this(i)),8&a)return i;if("object"===typeof i&&i){if(4&a&&i.__esModule)return i;if(16&a&&"function"===typeof i.then)return i}var o=Object.create(null);n.r(o);var s={};e=e||[null,t({}),t([]),t(t)];for(var l=2&a&&i;"object"==typeof l&&!~e.indexOf(l);l=t(l))Object.getOwnPropertyNames(l).forEach((function(e){s[e]=function(){return i[e]}}));return s["default"]=function(){return i},n.d(o,s),o}}(),function(){n.d=function(e,t){for(var i in t)n.o(t,i)&&!n.o(e,i)&&Object.defineProperty(e,i,{enumerable:!0,get:t[i]})}}(),function(){n.f={},n.e=function(e){return Promise.all(Object.keys(n.f).reduce((function(t,i){return n.f[i](e,t),t}),[]))}}(),function(){n.u=function(e){return"js/webfontloader.628f3798.js"}}(),function(){n.miniCssF=function(e){}}(),function(){n.g=function(){if("object"===typeof globalThis)return globalThis;try{return this||new Function("return this")()}catch(e){if("object"===typeof window)return window}}()}(),function(){n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)}}(),function(){var e={},t="correct-study-design:";n.l=function(i,a,o,s){if(e[i])e[i].push(a);else{var l,r;if(void 0!==o)for(var c=document.getElementsByTagName("script"),u=0;u<c.length;u++){var d=c[u];if(d.getAttribute("src")==i||d.getAttribute("data-webpack")==t+o){l=d;break}}l||(r=!0,l=document.createElement("script"),l.charset="utf-8",l.timeout=120,n.nc&&l.setAttribute("nonce",n.nc),l.setAttribute("data-webpack",t+o),l.src=i),e[i]=[a];var p=function(t,n){l.onerror=l.onload=null,clearTimeout(h);var a=e[i];if(delete e[i],l.parentNode&&l.parentNode.removeChild(l),a&&a.forEach((function(e){return e(n)})),t)return t(n)},h=setTimeout(p.bind(null,void 0,{type:"timeout",target:l}),12e4);l.onerror=p.bind(null,l.onerror),l.onload=p.bind(null,l.onload),r&&document.head.appendChild(l)}}}(),function(){n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})}}(),function(){n.nmd=function(e){return e.paths=[],e.children||(e.children=[]),e}}(),function(){n.p="/clinical-research-study-design/"}(),function(){var e={524:0};n.f.j=function(t,i){var a=n.o(e,t)?e[t]:void 0;if(0!==a)if(a)i.push(a[2]);else{var o=new Promise((function(n,i){a=e[t]=[n,i]}));i.push(a[2]=o);var s=n.p+n.u(t),l=new Error,r=function(i){if(n.o(e,t)&&(a=e[t],0!==a&&(e[t]=void 0),a)){var o=i&&("load"===i.type?"missing":i.type),s=i&&i.target&&i.target.src;l.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",l.name="ChunkLoadError",l.type=o,l.request=s,a[1](l)}};n.l(s,r,"chunk-"+t,t)}},n.O.j=function(t){return 0===e[t]};var t=function(t,i){var a,o,s=i[0],l=i[1],r=i[2],c=0;if(s.some((function(t){return 0!==e[t]}))){for(a in l)n.o(l,a)&&(n.m[a]=l[a]);if(r)var u=r(n)}for(t&&t(i);c<s.length;c++)o=s[c],n.o(e,o)&&e[o]&&e[o][0](),e[o]=0;return n.O(u)},i=self["webpackChunkcorrect_study_design"]=self["webpackChunkcorrect_study_design"]||[];i.forEach(t.bind(null,0)),i.push=t.bind(null,i.push.bind(i))}();var i=n.O(void 0,[504],(function(){return n(82275)}));i=n.O(i)})();
//# sourceMappingURL=app.460a51d2.js.map